Short Interest in Allarity Therapeutics, Inc. (NASDAQ:ALLR) Declines By 21.9%

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the target of a significant drop in short interest during the month of December. As of December 15th, there was short interest totaling 265,860 shares, a drop of 21.9% from the November 30th total of 340,426 shares. Based on an average daily volume of 166,993 shares, the days-to-cover ratio is presently 1.6 days. Currently, 1.7% of the shares of the stock are sold short. Currently, 1.7% of the shares of the stock are sold short. Based on an average daily volume of 166,993 shares, the days-to-cover ratio is presently 1.6 days.

Hedge Funds Weigh In On Allarity Therapeutics

Large investors have recently bought and sold shares of the business. Jane Street Group LLC purchased a new stake in Allarity Therapeutics in the second quarter worth $27,000. Geode Capital Management LLC grew its holdings in shares of Allarity Therapeutics by 49.3% in the second quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock worth $51,000 after purchasing an additional 16,729 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Allarity Therapeutics in the second quarter worth about $51,000. Citadel Advisors LLC purchased a new position in Allarity Therapeutics in the 3rd quarter worth about $149,000. Finally, Private Advisor Group LLC bought a new stake in Allarity Therapeutics during the 3rd quarter valued at about $441,000. Hedge funds and other institutional investors own 11.53% of the company’s stock.

Allarity Therapeutics Trading Up 6.9%

Shares of NASDAQ:ALLR opened at $1.08 on Thursday. Allarity Therapeutics has a 12 month low of $0.61 and a 12 month high of $2.35. The company has a market capitalization of $17.06 million, a price-to-earnings ratio of -1.83 and a beta of 0.23. The firm’s 50-day moving average is $1.17 and its 200 day moving average is $1.24.

Allarity Therapeutics (NASDAQ:ALLR) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.04. As a group, equities analysts forecast that Allarity Therapeutics will post -78.08 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Allarity Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 20th. Weiss Ratings restated a “sell (e+)” rating on shares of Allarity Therapeutics in a research report on Wednesday, October 8th. Finally, Ascendiant Capital Markets raised their price objective on Allarity Therapeutics from $9.25 to $9.50 and gave the company a “buy” rating in a research note on Tuesday, December 9th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Allarity Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $9.50.

Allarity Therapeutics Company Profile

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.